Meng Li, Xu Le, Yang Yuanfeng, Zhou Lin, Chang Yuan, Shi Tianming, Tan Cheng, An Huimin, Zhu Yu, Xu Jiejie
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Oncotarget. 2017 May 9;8(37):61036-61047. doi: 10.18632/oncotarget.17717. eCollection 2017 Sep 22.
Some of the fucosylation catalyzed by fucosyltransferase-III mediates the epithelial-mesenchymal transition and enhances tumor cell-macrophage signaling, which promotes malignant transforming and immune evasion. The aim of the study was to investigate the association between the expression of fucosyltransferase-III and clinical outcomes of patients with clear-cell renal cell carcinoma after surgery.
High fucosyltransferase-III expression was associated with a greater risk of recurrence ( = 0.002) and shortened overall survival ( < 0.001). We then established a prognostic nomogram including tumor size, pathologic T, N, M stage, coagulative necrosis, lymphovascular invasion and fucosyltransferase-III expression. Furthermore, the predictive accuracy of the Leibovich prognostic score was improved when fucosyltransferase-III expression was added ( = 0.009 for overall survival and = 0.002 for recurrence-free survival).
We conducted a retrospective cohort study of 406 patients who underwent partial or radical nephrectomy between January 2008 and December 2009 in a single institute. Fucosyltransferase-III expression levels were evaluated by immunohistochemical staining in tumor tissues. Kaplan-Meier method was applied to compare survival curves. Cox regression models were fitted to analyze the effect of prognostic factors on recurrence-free and overall survival. Harrell's concordance index and Akaike's Information Criteria were calculated to assess predictive accuracy.
Fucosyltransferase-III is a predictive factor for poor overall survival and recurrence free survival in patients with ccRCC. The inhibitor of fucosyltransferase-III might be a potential therapeutic method for the disease.
岩藻糖基转移酶III催化的一些岩藻糖基化作用介导上皮-间质转化并增强肿瘤细胞-巨噬细胞信号传导，从而促进恶性转化和免疫逃逸。本研究旨在探讨岩藻糖基转移酶III的表达与透明细胞肾细胞癌患者术后临床结局之间的关联。
岩藻糖基转移酶III高表达与更高的复发风险（P = 0.002）及缩短的总生存期（P < 0.001）相关。然后我们建立了一个预后列线图，纳入肿瘤大小、病理T、N、M分期、凝固性坏死、脉管浸润和岩藻糖基转移酶III表达。此外，加入岩藻糖基转移酶III表达后，Leibovich预后评分的预测准确性得到提高（总生存期P = 0.009，无复发生存期P = 0.002）。
我们对2008年1月至2009年12月在一家机构接受部分或根治性肾切除术的406例患者进行了一项回顾性队列研究。通过免疫组织化学染色评估肿瘤组织中岩藻糖基转移酶III的表达水平。应用Kaplan-Meier法比较生存曲线。采用Cox回归模型分析预后因素对无复发生存期和总生存期的影响。计算Harrell一致性指数和赤池信息准则以评估预测准确性。
岩藻糖基转移酶III是ccRCC患者总生存期和无复发生存期较差的预测因素。岩藻糖基转移酶III抑制剂可能是该疾病的一种潜在治疗方法。
